


## I. Biostatistics Refresher

- A. Importance of Biostatistics
  - i. Too much data coming out today
  - ii. Researchers / biostatisticians are potentially “fudging” data to make things look better than they actually are
  - iii. Up to practicing clinicians to look at the trials and see what they are really saying.
- B. Fear of Statistics
  - i. Everyone will have a fear of biostatistics
  - ii. Those that are comfortable with statistics are usually conscious of subtleties
- C. What we really need to know and do
  - i. Statistics is not meant to be scary
  - ii. Many times we pay too much attention statistical methods and not enough evaluating the validity / applicability of the study.
  - iii. Poor statistical methods happen and can misrepresent data, but if we are aware of some stats basics, most can be avoided.

## II. The Basics

- A. Mean, median, mode, standard deviation
  - i. Mean: average
  - ii. Median: place ALL data in order from highest to lowest; middle number
  - iii. MODE: value occurring with the greatest frequency
- B. Nominal, ordinal, continuous
  - i. Nominal
    - a. categories (yes/no, male/female, white/black/asian/indian, etc.)
    - b. numbers assigned to categories to make classification easier
    - c. numbers have NO value; do not indicate importance, severity, etc.
  - ii. Ordinal
    - a. number assignments have value (NYHA classes, Leichert scale)
    - b. values represent a *meaningful* order (order of ranges)
    - c. relationship/difference between numbers is not quantifiable
  - iii. Continuous
    - a. Interval
      - a. the actual number/value (temp in Celsius / Fahrenheit)
      - b. scales DO NOT have an absolute zero
    - b. Ratio
      - a. Same as interval data, but DOES have an absolute zero (i.e. temp in Kelvin, BP, HR, weight)
      - b. Can truly quantify differences between two values of same measurement

- C. Population, sample, normal distribution, standard deviation
- Population: Everyone (and their sister)
  - Sample: select group / defined group from the population
  - Normal distribution: representation of many naturally occurring phenomena
  - Standard deviation: indicates percentages/groups/areas above and below the mean
    - Standard Error of the Mean (SEM)
    - Z-score



### **Normal Distribution**

- D. Null & alternative hypothesis
- Null hypothesis: the opposite of the hypothesis proposed
    - typically, the idea that a difference does not exist
    - "fail to reject the null hypothesis"
  - Alternative hypothesis: The idea being researched and/or evaluated
    - typically, the idea that a difference exists
    - what researchers are testing for
      - superiority
      - inferiority
      - equivalency
- E.  $\alpha$  (false positives, type I error),  $\beta$  (false negatives type II error), confidence interval, power
- $\alpha$  (false positives; typically 0.05): falsely reject the null hypothesis
    - falsely accept the alternative
    - make the statement your idea is true, when it is really false
  - $\beta$  (false negatives): falsely accept the null hypothesis
    - falsely reject the alternative
    - make the statement your idea is false, when it is really true
  - Power (P; typically 0.80)
    - ability of a test to detect if the null hypothesis is acceptable
    - ability / probability to avoid type II error
    - power =  $1 - \beta$

- iv. Confidence interval (CI)
  - a. % range from the normal distribution
  - b. if the same study were conducted 100 times, the results should fall in this % range of normal distribution, that % of the time (i.e. 95% confidence interval means a study should / would produce similar results 95 out of 100 times)
  - c. any value in a confidence interval has the same likelihood of occurring as any other value (i.e. a result of 1.3 with a 95% confidence interval of 0.6 to 2.0 means ANY VALUE from 0.6 to 2.0 has a chance of occurring 95% of the time)
  - d. confidence interval =  $1 - \alpha$
- v. NOTE: if you are not able to reject the null hypothesis (accept the alternative), make sure to check that the study met its power (ability to detect a false negative)

**Actual Answer**

		Actual Answer	
		+	-
Tested / Result Answer	+	Correct	Type II error
	-	Type I error	Correct

### III. Study Types

- A. Case reports, case controls, cohorts
  - i. Case report: identifies single to multiple (3-4) events that has been caused by an outside / unique situation (i.e. drug, diet, habit, etc.)
  - ii. Case control: identifies an OUTCOME and then looks at subjects retrospectively (backwards) for commonalities
  - iii. Cohort: identifies a population, typically with something in COMMON, and then follows them looking for an outcome (i.e. Framingham, Mass.)
  - iv. Clinical trial: tests a hypothesis against a control
    - a. design (crossover, independent groups)
    - b. randomized (simple, blocked, stratified)
    - c. blinding (single blind, double blind, triple blind)
    - d. control (placebo, standard of care)
  - v. Meta-analysis: compilation of clinical trials with similar design and measured outcomes to "simulate" a large clinical trial
  - vi. Systematic Review: similar to meta-analysis, but with highly scrutinized methods
    - a. hardest to perform
    - b. highest reliability for interpreting evidence
    - c. Cochrane Systematic Reviews / Analysis

#### IV. Reporting the Results

##### A. p-value

- i. the most popular statistical value
- ii. reports the probability of a result actually being true (sounds like an  $\alpha$ )
- iii. most accepted as p-value < 0.05 being
- iv. as long as the p-value is less than what it is set to be, the results can be considered *statistically* significant
- v. NOTE: lower p-values do not indicate importance / magnitude of significance (i.e. p-value = 0.048 is NOT more significant than p-value = 0.0000001)

##### B. Odds ratio, relative risk, and relative risk reduction

- i. Odds ratio (OR): reported with case control studies
  - a. Reports how many times more likely a sample population are to have been exposed to a variable, given their current status
  - b. Value = 1.0; no relationship between outcome and variable exposure
  - c. Value < 1.0; patient with outcome is *less* likely to have been exposed
  - d. Value > 1.0; patient with outcome is *more* likely to have been exposed

$$OR = \frac{[\text{Group A \# exposed} / \text{Group A total}]}{[\text{Group B \# exposed} / \text{Group B total}]}$$

- ii. Relative Risk (RR): reported with cohort studies
  - a. Reports how many times more likely a population is to experience an outcome, given presence (or absence) of a variable.
  - b. Value = 1.0; no relationship between variable and outcome
  - c. Value < 1.0; presence of variable makes the measured outcome *less* likely
  - d. Value > 1.0; presence of variable makes the measured outcome *more* likely

$$RR = \frac{[\text{Group A \# event} / \text{Group A total}]}{[\text{Group B \# event} / \text{Group B total}]}$$

- iii. If a CI value (for either OR or RR) falls both below and above 1.0, the results cannot be considered significant because there is an equal chance of an outcome / variable and variable being *less* AND *more* likely related to the variable / outcome

- iv. Relative Risk Reduction (RRR)
  - a. % difference in chance of an outcome, given exposure to a variable
  - b. RRR = zero; no relationship between variable and outcome
  - c. RRR < zero; presence of variable makes the measured outcome *more* likely
  - d. RRR > zero; presence of variable makes the measured outcome *less* likely
- e.  $RRR = 1 - RR$
- v. If a CI value (for RRR) is both above and below ZERO, the results cannot be considered significant because there is an equal chance of an outcome and variable being *less* AND *more* likely related.
- vi. Absolute Relative Risk (ARR): absolute difference between chance of outcome, given variable exposure and NO outcome, given variable exposure.

$$ARR = \left| \frac{[\text{Group A \# event}]}{[\text{Group A total}]} - \frac{[\text{Group B \# event}]}{[\text{Group B total}]} \right|$$

- C. Number need to treat, number needed to harm
  - i. Number needed to treat: how many individuals from the control group would have to be exposed with the hypothesis to prevent / cause one outcome
    - a. i.e. how many people with HTN and NOT taking aspirin need to be treated with aspirin to save one life
  - ii. Number needed to harm: how many individuals from the control group need to be exposed to a variable to cause one adverse event
    - a. i.e. how many people with HTN and not taking ASA need to be treated with ASA to cause a specific adverse event

$$NNT \text{ (or NNH)} = 1 / \left| \frac{[\text{Group A \# event}]}{[\text{Group A total}]} - \frac{[\text{Group B \# event}]}{[\text{Group B total}]} \right|$$

- iii. Typically, NNT and NNH < 50 are considered *clinically* significant
  - a. NNT < 50 is GOOD
  - b. NNH < 50 is BAD

## V. Who Cares

- A. Ask the following questions:
  - i. Do the results make sense?
  - ii. Do the results mean anything to my individual patient?
  - iii. Do the results mean anything to my patient population (internal vs. external validity)?

**VI. More information**

- A. Annals of Emergency Medicine Series: *Introduction to Biostatistics*
  - i. Part 1: basic concepts. Ann Emerg Med 1990;86-89
  - ii. Part 2: descriptive statistics. Ann Emerg Med 1990;309-315
  - iii. Part 3: sensitivity, specificity, predictive value, and hypothesis testing. Ann Emerg Med 1990;591-7
  - iv. Part 4: statistical inference techniques in hypothesis testing. Ann Emerg Med 1990;820-5
  - v. Part 5: statistical inference techniques for hypothesis testing with nonparametric data. Ann Emerg Med 1990;1054-9
  - vi. Part 6: correlation and regression. Ann Emerg Med 1990;1462-8
- B. Cho, MK and L Bero. Instruments for assessing the quality of drug studies published in the medical literature. JAMA 1994;272(2):101-4
- C. *High Yield Biostatistics*, 2<sup>nd</sup> ed. by Glasser, Anthony N. Lippincott Williams & Wilkins 2001.
- D. *Studying a Study and Testing a Test*, 4<sup>th</sup> ed. By Riegelman, Richard K. Lippincott Williams & Wilkins 2000.
- E. Glasser SP & Howard G. Clinical Trial Design Issues: At Least 10 Things You Should Look For in Clinical Trials. J. Clin. Pharmacol., Oct 2006; 46: 1106 - 1115